Weebit Nano (ASX: WBT) appoints Eran Briman as VP Marketing & Business Development
Mr Briman has extensive industry experience, commencing his career developing embedded Digital Signal Processors (DSPs) at DSP Group Inc., which later formed the foundation of CEVA Inc (NASDAQ: CEVA). As VP Marketing and Corporate Development at CEVA, Mr Briman was instrumental in growing the business to become the world's number one DSP IP licensor.
Rat’s Rant – The German Late Night Blitz Edition
Rat's Rant - The German Late Night Blitz Edition
What's Hot - GLA, AOA, SBR, WCG, FFR, LBY, MGT, RSH, DRE, OAR, BNL & OLL
What's Not - PXS & HMX
What's Doing - The Great Unwashed Protesters
Closet to the Pin - Leader board update and zero commentary
Rat’s Rant – The Wall Street Bomb Edition
What's Hot - EER, GGE, ICI, CLA, FPL, SHE, TEG, WWI, BNL & CYPWhat's Not - FFRWhat's Doing...
Rat’s Rant – The Russian Bomb Edition
What's Hot - TSC, FFR, CCA, DEV, CAV, RIM, MYQ, 88E, BNL & 3DA What's Not - NEA &...
Rat’s Rant – The French Execution Edition
What's Hot - JXT, LCL, QFY, DRO, SHO, 3DA, TMT, PUR, AQD & AGH What's Not - MYRWhat's Doing...
Rat’s Rant – The Oprah Winfrey Edition
What's Hot - LRS, DTZ, BRN, OAU, BGT, CDP, CZR, CRL & VUL What's Not - SBR &...
Rat’s Rant – The Thailand BNPL Edition
What's Hot - 4DS, SBW, DW8, GED, WWI, AVL, LRS & ECS What's Not - PBHWhat's Doing - BNPL...
Rat’s Rant – The Golden Girls Edition
Rat's Rant - The Golden Girls Edition
8common (ASX: 8CO) Announces CardHero Launch Following the Signing of EML Agreement
8common has signed a 3-year agreement with EML Payments Limited to issue prepaid Mastercards through the company’s CardHero platformThe agreement with EML enables the...
8common (ASX: 8CO) Announces Six new Federal Government entities signed to expense8 with total...
Five new Federal Government entities under the Service Delivery Office (SDO) of the Department of Finance shared services hub sign onto expense8Total...
Latest News
Why VBI Vaccines (NASDAQ: VBIV) Could Be a Contrarian Investor’s Dream
While the list of those garnering the most attention read like the usual suspects, there’s probably one biotech firm you haven’t heard of, VBI Vaccines (NASDAQ:VBIV). While VBIV stock soared to multi-year highs around mid-July, shares have found themselves plummeting back to earth. As several now well-known vaccine companies have entered into late-stage clinical trials for their Covid-19 candidates, the other, smaller names have lost their luster.
